NAV
$16.44
AUM
$73.4M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.39
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +0.82% | +15.92% | -3.91% | +0.94% | -1.28% | -14.82% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | 1801.HK | Innovent Biologics Inc | 9.00% |
| 2 | 6160.HK | BeOne Medicines Ltd Ordinary Shares | 8.79% |
| 3 | 2269.HK | WuXi Biologics (Cayman) Inc | 7.21% |
| 4 | 603259.SS | Wuxi AppTec Co Ltd Class A | 6.12% |
| 5 | 600276.SS | Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 4.44% |
| 6 | 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 4.22% |
| 7 | 9926.HK | Akeso Inc Ordinary Shares | 4.19% |
| 8 | 1177.HK | Sino Biopharmaceutical Ltd | 3.80% |
| 9 | 02359 | Wuxi AppTec Co Ltd | 3.53% |
| 10 | 3692.HK | Hansoh Pharmaceutical Group Co Ltd | 3.44% |
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Inception Date: 2018-01-31